{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T17:35:57Z","timestamp":1758476157961},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2018,9,14]],"date-time":"2018-09-14T00:00:00Z","timestamp":1536883200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1245\/s10434-018-6750-9","type":"journal-article","created":{"date-parts":[[2018,9,16]],"date-time":"2018-09-16T00:30:13Z","timestamp":1537057813000},"page":"3453-3459","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Adjuvant and Neoadjuvant Therapy, Treatment for Advanced Disease, and Genetic Considerations for Adrenocortical Carcinoma: An Update from the SSO Endocrine and Head and Neck Disease Site Working Group"],"prefix":"10.1245","volume":"25","author":[{"given":"Paxton V.","family":"Dickson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lawrence","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tina W. F.","family":"Yen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth G.","family":"Grubbs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dhavel","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmen C.","family":"Sol\u00f3rzano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,9,14]]},"reference":[{"issue":"23","key":"6750_CR1","doi-asserted-by":"publisher","first-page":"2372","DOI":"10.1056\/NEJMoa063360","volume":"356","author":"M Terzolo","year":"2007","unstructured":"Terzolo M, Angeli A, Fassnacht M, et al. Adjuvant mitotane treatment for adrenocortical carcinoma. N Engl J Med. 2007;356(23):2372\u20132380.","journal-title":"N Engl J Med"},{"issue":"4","key":"6750_CR2","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1210\/jc.2016-2894","volume":"102","author":"A Berruti","year":"2017","unstructured":"Berruti A, Grisanti S, Pulzer A, et al. Long-term outcomes of adjuvant mitotane therapy in patients with radically resected adrenocortical carcinoma. J Clin Endocrinol Metab. 2017;102(4):1358\u20131365.","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"6750_CR3","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1210\/jc.2013-2856","volume":"99","author":"T Else","year":"2014","unstructured":"Else T, Williams AR, Sabolch A, Jolly S, Miller BS, Hammer GD. Adjuvant therapies and patient and tumor characteristics associated with survival of adult patients with adrenocortical carcinoma. J Clin Endocrinol Metab. 2014;99(2):455\u2013461.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"6750_CR4","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1245\/s10434-009-0716-x","volume":"17","author":"EG Grubbs","year":"2010","unstructured":"Grubbs EG, Callender GG, Xing Y, et al. Recurrence of adrenal cortical carcinoma following resection: surgery alone can achieve results equal to surgery plus mitotane. Ann Surg Oncol. 2010;17(1):263\u2013270.","journal-title":"Ann Surg Oncol"},{"issue":"4","key":"6750_CR5","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1016\/j.jamcollsurg.2015.12.013","volume":"222","author":"LM Postlewait","year":"2016","unstructured":"Postlewait LM, Ethun CG, Tran TB, et al. Outcomes of adjuvant mitotane after resection of adrenocortical carcinoma: a 13-institution study by the US adrenocortical carcinoma group. J Am Coll Surg. 2016;222(4):480\u2013490.","journal-title":"J Am Coll Surg"},{"issue":"5","key":"6750_CR6","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1038\/bjc.1994.183","volume":"69","author":"HR Haak","year":"1994","unstructured":"Haak HR, Hermans J, van de Velde CJ, et al. Optimal treatment of adrenocortical carcinoma with mitotane: results in a consecutive series of 96 patients. Br J Cancer. 1994;69(5):947\u2013951.","journal-title":"Br J Cancer"},{"issue":"1","key":"6750_CR7","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/0277-5379(84)90033-6","volume":"20","author":"H Slooten van","year":"1984","unstructured":"van Slooten H, Moolenaar AJ, van Seters AP, Smeenk D. The treatment of adrenocortical carcinoma with o,p\u2019-DDD: prognostic implications of serum level monitoring. Eur J Cancer Clin Oncol. 1984;20(1):47\u201353.","journal-title":"Eur J Cancer Clin Oncol"},{"issue":"3","key":"6750_CR8","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1677\/erc.1.01029","volume":"12","author":"DE Schteingart","year":"2005","unstructured":"Schteingart DE, Doherty GM, Gauger PG, et al. Management of patients with adrenal cancer: recommendations of an international consensus conference. Endocr Relat Cancer. 2005;12(3):667\u2013680.","journal-title":"Endocr Relat Cancer"},{"issue":"6","key":"6750_CR9","doi-asserted-by":"publisher","first-page":"705","DOI":"10.4158\/EP161719.RA","volume":"23","author":"BS Miller","year":"2017","unstructured":"Miller BS, Else T. AACE adrenal scientific committee. Personalized care of patients with adrenocortical carcinoma: a comprehensive approach. Endocr Pract. 2017;23(6):705\u2013715.","journal-title":"Endocr Pract"},{"issue":"2","key":"6750_CR10","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.ecl.2018.02.003","volume":"47","author":"S Puglisi","year":"2018","unstructured":"Puglisi S, Perotti P, Pia A, Reimondo G, Terzolo M. Adrenocortical Carcinoma with Hypercortisolism. Endocrinol Metab Clin North Am. 2018;47(2):395\u2013407.","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"3","key":"6750_CR11","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1046\/j.1365-2265.2003.01881.x","volume":"60","author":"B Allolio","year":"2004","unstructured":"Allolio B, Hahner S, Weismann D, Fassnacht M. Management of adrenocortical carcinoma. Clin Endocrinol (Oxf). 2004;60(3):273\u2013287.","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"11","key":"6750_CR12","doi-asserted-by":"publisher","first-page":"4501","DOI":"10.1210\/jc.2006-1007","volume":"91","author":"M Fassnacht","year":"2006","unstructured":"Fassnacht M, Hahner S, Polat B, et al. Efficacy of adjuvant radiotherapy of the tumor bed on local recurrence of adrenocortical carcinoma. J Clin Endocrinol Metab. 2006;91(11):4501\u20134504.","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"6750_CR13","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.ijrobp.2015.01.007","volume":"92","author":"A Sabolch","year":"2015","unstructured":"Sabolch A, Else T, Griffith KA, et al. Adjuvant radiation therapy improves local control after surgical resection in patients with localized adrenocortical carcinoma. Int J Radiat Oncol Biol Phys. 2015;92(2):252\u2013259.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"6750_CR14","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s12672-015-0241-2","volume":"7","author":"AO Hoff","year":"2016","unstructured":"Hoff AO, Berruti A. 5th international ACC symposium: future and current therapeutic trials in adrenocortical Carcinoma. Horm Cancer. 2016;7(1):29\u201335.","journal-title":"Horm Cancer"},{"issue":"6","key":"6750_CR15","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1007\/s00268-014-2484-4","volume":"38","author":"BK Bednarski","year":"2014","unstructured":"Bednarski BK, Habra MA, Phan A, et al. Borderline resectable adrenal cortical carcinoma: a potential role for preoperative chemotherapy. World J Surg. 2014;38(6):1318\u20131327.","journal-title":"World J Surg"},{"issue":"3","key":"6750_CR16","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1677\/erc.1.01025","volume":"12","author":"A Berruti","year":"2005","unstructured":"Berruti A, Terzolo M, Sperone P, et al. Etoposide, doxorubicin and cisplatin plus mitotane in the treatment of advanced adrenocortical carcinoma: a large prospective phase II trial. Endocr Relat Cancer. 2005;12(3):657\u2013666.","journal-title":"Endocr Relat Cancer"},{"issue":"23","key":"6750_CR17","doi-asserted-by":"publisher","first-page":"2189","DOI":"10.1056\/NEJMoa1200966","volume":"366","author":"M Fassnacht","year":"2012","unstructured":"Fassnacht M, Terzolo M, Allolio B, et al. Combination chemotherapy in advanced adrenocortical carcinoma. N Engl J Med. 2012;366(23):2189\u20132197.","journal-title":"N Engl J Med"},{"issue":"4","key":"6750_CR18","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1016\/S1470-2045(15)70081-1","volume":"16","author":"M Fassnacht","year":"2015","unstructured":"Fassnacht M, Berruti A, Baudin E, et al. Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a double-blind, randomised, phase 3 study. Lancet Oncol. 2015;16(4):426\u2013435.","journal-title":"Lancet Oncol"},{"issue":"8","key":"6750_CR19","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1003466","volume":"363","author":"FS Hodi","year":"2010","unstructured":"Hodi FS, O\u2019Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711\u2013723.","journal-title":"N Engl J Med"},{"issue":"19","key":"6750_CR20","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","volume":"375","author":"M Reck","year":"2016","unstructured":"Reck M, Rodriguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016;375(19):1823\u20131833.","journal-title":"N Engl J Med"},{"issue":"13","key":"6750_CR21","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1016\/0024-3205(95)00045-8","volume":"56","author":"GH Wolfgang","year":"1995","unstructured":"Wolfgang GH, MacDonald JR, Vernetti LA, Pegg DG, Robertson DG. Biochemical alterations in guinea pig adrenal cortex following administration of PD 132301-2, an inhibitor of acyl-CoA:cholesterol acyltransferase. Life Sci. 1995;56(13):1089\u20131093.","journal-title":"Life Sci"},{"issue":"1","key":"6750_CR22","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s12672-015-0242-1","volume":"7","author":"RE Krijger de","year":"2016","unstructured":"de Krijger RE, Bertherat J. 5th International ACC symposium: classification of adrenocortical cancers from pathology to integrated genomics: real advances or lost in translation? Horm Cancer. 2016;7(1):3\u20138.","journal-title":"Horm Cancer"},{"issue":"4","key":"6750_CR23","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/nrendo.2013.272","volume":"10","author":"G Assie","year":"2014","unstructured":"Assie G, Jouinot A, Bertherat J. The \u2018omics\u2019 of adrenocortical tumours for personalized medicine. Nat Rev Endocrinol. 2014;10(4):215\u2013228.","journal-title":"Nat Rev Endocrinol"},{"issue":"5","key":"6750_CR24","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1016\/j.ccell.2016.04.002","volume":"29","author":"S Zheng","year":"2016","unstructured":"Zheng S, Cherniack AD, Dewal N, et al. Comprehensive pan-genomic characterization of adrenocortical carcinoma. Cancer Cell. 2016;29(5):723\u2013736.","journal-title":"Cancer Cell"},{"issue":"7","key":"6750_CR25","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1200\/JCO.2008.18.5678","volume":"27","author":"A Reynies de","year":"2009","unstructured":"de Reynies A, Assie G, Rickman DS, et al. Gene expression profiling reveals a new classification of adrenocortical tumors and identifies molecular predictors of malignancy and survival. J Clin Oncol. 2009;27(7):1108\u20131115.","journal-title":"J Clin Oncol"},{"issue":"1\u20132","key":"6750_CR26","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.mce.2013.10.028","volume":"386","author":"AM Lerario","year":"2014","unstructured":"Lerario AM, Moraitis A, Hammer GD. Genetics and epigenetics of adrenocortical tumors. Mol Cell Endocrinol. 2014;386(1-2):67\u201384.","journal-title":"Mol Cell Endocrinol"},{"key":"6750_CR27","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/978-3-319-29998-3_8","volume":"205","author":"A Angelousi","year":"2016","unstructured":"Angelousi A, Zilbermint M, Berthon A, Espiard S, Stratakis CA. Diagnosis and Management of Hereditary Adrenal Cancer. Recent Results Cancer Res. 2016;205:125-147.","journal-title":"Recent Results Cancer Res"},{"issue":"5","key":"6750_CR28","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1053\/j.seminoncol.2016.08.007","volume":"43","author":"EJ Petr","year":"2016","unstructured":"Petr EJ, Else T. Genetic predisposition to endocrine tumors: diagnosis, surveillance and challenges in care. Semin Oncol. 2016;43(5):582\u2013590.","journal-title":"Semin Oncol"},{"issue":"2","key":"6750_CR29","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1158\/0008-5472.427.65.2","volume":"65","author":"LL Bachinski","year":"2005","unstructured":"Bachinski LL, Olufemi SE, Zhou X, et al. Genetic mapping of a third Li-Fraumeni syndrome predisposition locus to human chromosome 1q23. Cancer Res. 2005;65(2):427\u2013431.","journal-title":"Cancer Res"},{"issue":"1","key":"6750_CR30","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1210\/jc.2012-2198","volume":"98","author":"VM Raymond","year":"2013","unstructured":"Raymond VM, Else T, Everett JN, Long JM, Gruber SB, Hammer GD. Prevalence of germline TP53 mutations in a prospective series of unselected patients with adrenocortical carcinoma. J Clin Endocrinol Metab. 2013;98(1):119\u2013125.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"6750_CR31","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1097\/CCO.0b013e328333bf00","volume":"22","author":"EI Palmero","year":"2010","unstructured":"Palmero EI, Achatz MI, Ashton-Prolla P, Olivier M, Hainaut P. Tumor protein 53 mutations and inherited cancer: beyond Li-Fraumeni syndrome. Curr Opin Oncol. 2010;22(1):64\u201369.","journal-title":"Curr Opin Oncol"},{"issue":"3","key":"6750_CR32","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1158\/1078-0432.CCR-06-2085","volume":"13","author":"R Libe","year":"2007","unstructured":"Libe R, Groussin L, Tissier F, et al. Somatic TP53 mutations are relatively rare among adrenocortical cancers with the frequent 17p13 loss of heterozygosity. Clin Cancer Res. 2007;13(3):844\u2013850.","journal-title":"Clin Cancer Res."},{"issue":"1","key":"6750_CR33","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1136\/jmg.38.1.43","volume":"38","author":"A Chompret","year":"2001","unstructured":"Chompret A, Abel A, Stoppa-Lyonnet D, et al. Sensitivity and predictive value of criteria for p53 germline mutation screening. J Med Genet. 2001;38(1):43\u201347.","journal-title":"J Med Genet"},{"issue":"24","key":"6750_CR34","doi-asserted-by":"publisher","first-page":"3012","DOI":"10.1200\/JCO.2012.48.0988","volume":"31","author":"VM Raymond","year":"2013","unstructured":"Raymond VM, Everett JN, Furtado LV, et al. Adrenocortical carcinoma is a lynch syndrome-associated cancer. J Clin Oncol. 2013;31(24):3012\u20133018.","journal-title":"J Clin Oncol"},{"issue":"4","key":"6750_CR35","doi-asserted-by":"publisher","first-page":"e94170","DOI":"10.1371\/journal.pone.0094170","volume":"9","author":"Y Liu","year":"2014","unstructured":"Liu Y, Chew MH, Goh XW, et al. Systematic study on genetic and epimutational profile of a cohort of Amsterdam criteria-defined Lynch Syndrome in Singapore. PLoS One. 2014;9(4):e94170.","journal-title":"PLoS One"},{"issue":"6","key":"6750_CR36","doi-asserted-by":"publisher","first-page":"2269","DOI":"10.1210\/jc.2016-1460","volume":"101","author":"BG Challis","year":"2016","unstructured":"Challis BG, Kandasamy N, Powlson AS, et al. Familial adrenocortical carcinoma in association with lynch syndrome. J Clin Endocrinol Metab. 2016;101(6):2269\u20132272.","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"6750_CR37","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1530\/EJE-07-0635","volume":"158","author":"S Schaefer","year":"2008","unstructured":"Schaefer S, Shipotko M, Meyer S, et al. Natural course of small adrenal lesions in multiple endocrine neoplasia type 1: an endoscopic ultrasound imaging study. Eur J Endocrinol. 2008;158(5):699\u2013704.","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"6750_CR38","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1530\/EJE-11-0679","volume":"166","author":"B Gatta-Cherifi","year":"2012","unstructured":"Gatta-Cherifi B, Chabre O, Murat A, et al. Adrenal involvement in MEN1. Analysis of 715 cases from the Groupe d\u2019etude des Tumeurs Endocrines database. Eur J Endocrinol. 2012;166(2):269\u2013279.","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"6750_CR39","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1007\/s12672-015-0244-z","volume":"7","author":"T Else","year":"2016","unstructured":"Else T, Rodriguez-Galindo C. 5th International ACC symposium: hereditary predisposition to childhood ACC and the associated molecular phenotype: 5th international ACC symposium session: not just for kids! Horm Cancer. 2016;7(1):36\u201339.","journal-title":"Horm Cancer"},{"issue":"20","key":"6750_CR40","doi-asserted-by":"publisher","first-page":"2619","DOI":"10.1200\/JCO.2012.46.3711","volume":"31","author":"G Custodio","year":"2013","unstructured":"Custodio G, Parise GA, Kiesel Filho N, et al. Impact of neonatal screening and surveillance for the TP53 R337H mutation on early detection of childhood adrenocortical tumors. J Clin Oncol. 2013;31(20):2619\u20132626.","journal-title":"J Clin Oncol"},{"issue":"9","key":"6750_CR41","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1016\/S1470-2045(16)30249-2","volume":"17","author":"A Villani","year":"2016","unstructured":"Villani A, Shore A, Wasserman JD, et al. Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: 11\u00a0year follow-up of a prospective observational study. Lancet Oncol. 2016;17(9):1295\u20131305.","journal-title":"Lancet Oncol"},{"issue":"6","key":"6750_CR42","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/S1470-2045(11)70119-X","volume":"12","author":"A Villani","year":"2011","unstructured":"Villani A, Tabori U, Schiffman J, et al. Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: a prospective observational study. Lancet Oncol. 2011;12(6):559\u2013567.","journal-title":"Lancet Oncol"},{"issue":"9","key":"6750_CR43","doi-asserted-by":"publisher","first-page":"2990","DOI":"10.1210\/jc.2012-1230","volume":"97","author":"RV Thakker","year":"2012","unstructured":"Thakker RV, Newey PJ, Walls GV, et al. Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1). J Clin Endocrinol Metab. 2012;97(9):2990\u20133011.","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"6750_CR44","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1210\/jc.2013-2298","volume":"99","author":"C O\u2019Sullivan","year":"2014","unstructured":"O\u2019Sullivan C, Edgerly M, Velarde M, et al. The VEGF inhibitor axitinib has limited effectiveness as a therapy for adrenocortical cancer. J Clin Endocrinol Metab. 2014;99(4):1291\u20131297.","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"6750_CR45","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1530\/EJE-11-0918","volume":"166","author":"A Berruti","year":"2012","unstructured":"Berruti A, Sperone P, Ferrero A, et al. Phase II study of weekly paclitaxel and sorafenib as second\/third-line therapy in patients with adrenocortical carcinoma. Eur J Endocrinol. 2012;166(3):451\u2013458.","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"6750_CR46","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1530\/EJE-09-0804","volume":"162","author":"S Wortmann","year":"2010","unstructured":"Wortmann S, Quinkler M, Ritter C, et al. Bevacizumab plus capecitabine as a salvage therapy in advanced adrenocortical carcinoma. Eur J Endocrinol. 2010;162(2):349\u2013356.","journal-title":"Eur J Endocrinol"},{"issue":"6","key":"6750_CR47","doi-asserted-by":"publisher","first-page":"2057","DOI":"10.1210\/jc.2007-2564","volume":"93","author":"M Quinkler","year":"2008","unstructured":"Quinkler M, Hahner S, Wortmann S, et al. Treatment of advanced adrenocortical carcinoma with erlotinib plus gemcitabine. J Clin Endocrinol Metab. 2008;93(6):2057\u20132062.","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"6750_CR48","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1038\/bjc.2013.46","volume":"108","author":"A Naing","year":"2013","unstructured":"Naing A, Lorusso P, Fu S, et al. Insulin growth factor receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with metastatic adrenocortical carcinoma. Br J Cancer. 2013;108(4):826\u2013830.","journal-title":"Br J Cancer"},{"issue":"4","key":"6750_CR49","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1007\/s12672-014-0182-1","volume":"5","author":"AM Lerario","year":"2014","unstructured":"Lerario AM, Worden FP, Ramm CA, et al. The combination of insulin-like growth factor receptor 1 (IGF1R) antibody cixutumumab and mitotane as a first-line therapy for patients with recurrent\/metastatic adrenocortical carcinoma: a multi-institutional NCI-sponsored trial. Horm Cancer. 2014;5(4):232\u2013239.","journal-title":"Horm Cancer"}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1245\/s10434-018-6750-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-018-6750-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-018-6750-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T13:00:45Z","timestamp":1662037245000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1245\/s10434-018-6750-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,14]]},"references-count":49,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2018,11]]}},"alternative-id":["6750"],"URL":"https:\/\/doi.org\/10.1245\/s10434-018-6750-9","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,14]]},"assertion":[{"value":"1 April 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2018","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"None of the authors has any financial disclosures related to this work.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}